Skin toxicities, including acneiform skin rash and nail disorders, are well-known AEs of EGFR inhibitors [35], and previous meta-analysis from our research group also suggested higher risk of skin toxicities with cetuximab over bevacizumab [37]. The gene discussed is EGFR; the disease is nail disorder.